Á¦17ȸ ´ëÇѽÉÇ÷°üÁßÀçÇÐȸ ¿µ³²Áöȸ ½ÉÆ÷Áö¾ö : 2022-11-26±³À°ÀÏÀÚ : 2022-11-26
±³À°Àå¼Ò : °æÁÖ HICO
±³À°ÁÖÁ¦ :
Á¦17ȸ ´ëÇѽÉÇ÷°üÁßÀçÇÐȸ ¿µ³²Áöȸ ½ÉÆ÷Áö¾öÁÖÃÖ±â°ü : ´ëÇѽÉÇ÷°üÁßÀçÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ¿µ³²Áöȸ
´ã´çÀÚ : Á¶¿¹¸®
¿¬¶ôó : 02-582-8222
À̸ÞÀÏ :
yehc@kscvi.org ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 100¸í
Èñ¸ÁÆòÁ¡ : 5Á¡
Áö¿ª :
°æ»óºÏµµ±³À°½Ã°£ : 6 ½Ã°£ 55ºÐ
¼¼ºÎ¼ö°·á : 120,000¿ø
ºñ°í -Á¤È¸¿ø ¹«·á µî·Ï -Àü¹®ÀÇ/°³¿øÀÇ/ÀϹÝÀÇ: 60,000 -ÀüÀÓÀÇ/Àü°øÀÇ: 30,000 -°£È£»ç/ÀÇ·á±â»ç/ÀÇ´ë»ý/±ºÀÇ°ü/°øÁߺ¸°ÇÀÇ/ÀÓ»óº´¸®»ç/Àǹ«±â·Ï»ç: 20,000 -»ê¾÷ü/±âŸ: 120,000 * ÇöÀåµî·Ï¸¸ °¡´ÉÇÕ´Ï´Ù.
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 11-26 1F, 101-102È£ 09:00~09:10 2022 ESC(European Society of Cardiology) Guidline Update: Peri-operative Evaluation ¼Û¿©Á¤(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 11-26 1F, 101-102È£ 09:10~09:20 Big Data Analysis: Coronary Intervention Field ¹Ú°æ¹Î(¿ï»êÀÇ´ë)
±³À°½Ã°£ 11-26 1F, 101-102È£ 09:20~09:30 2022 ESC(European Society of Cardiology) Guidline Update: Peri-operative Handling of Antiplatelet Therapy ¿ÀÁØÇõ(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 11-26 1F, 101-102È£ 09:30~09:40 Distal Radial Approach: How to and When? ÀÌÁø¹è(´ë±¸°¡Å縯ÀÇ´ë)
Åä·Ð 11-26 1F, 101-102È£ 09:40~10:00 Discussion ()
ÈÞ½Ä 11-26 10:00~10:05 Break ()
±³À°½Ã°£ 11-26 1F, 101-102È£ 10:05~10:15 FFR(Fractional Flow Reserve) versus QFR(Quantitative Flow Ratio) ³²Ã¢¿í(°è¸íÀÇ´ë)
±³À°½Ã°£ 11-26 1F, 101-102È£ 10:15~10:25 INOCA(Ischemia and No Obstructive Coronary Artery Disease): Is This Real? °íÁø½Å(°æ»óÀÇ´ë)
±³À°½Ã°£ 11-26 1F, 101-102È£ 10:25~10:35 Natural Progression of High Risk Plaque ÇãÁ¤È£(°í½ÅÀÇ´ë)
±³À°½Ã°£ 11-26 1F, 101-102È£ 10:35~10:45 Stent Optimization: OCT(Optical Coherence Tomography)-guided À±ÇõÁØ(°è¸íÀÇ´ë)
Åä·Ð 11-26 1F, 101-102È£ 10:45~11:05 Discussion ()
ÈÞ½Ä 11-26 11:05~11:20 Coffee Break ()
±³À°½Ã°£ 11-26 1F, 101-102È£ 11:20~11:32 IVUS(Intravascular Ultrasonography) Based Tip Detection Method in CTO(Chronic Total Occlusion) PCI(Percutaneous Coronary Intervention) Katsuyuki Hasegawa(Higashi Takarazuka Satoh Hospital Japan)
±³À°½Ã°£ 11-26 1F, 101-102È£ 11:32~11:44 CTO(Chronic Total Occlusion) PCI(Percutaneous Coronary Intervention) Technique as a Rescue Strategy in a Complicated Situation Àü±¹Áø(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 11-26 1F, 101-102È£ 11:44~11:56 The Role of Drug-coated Balloon in the Treatment of CTO(Chronic Total Occlusion) Kazunori Masuda(Uji Tokusyukai Hospital Japan)
±³À°½Ã°£ 11-26 1F, 101-102È£ 11:56~12:08 Collateral Channel Selection Tool: The J-Channel Score ÀÌÀåÈÆ(°æºÏÀÇ´ë)
Åä·Ð 11-26 1F, 101-102È£ 12:08~12:20 Discussion ()
ÈÞ½Ä 11-26 12:20~12:25 Break ()
±³À°½Ã°£ 11-26 1F, 101-102È£ 12:25~12:45 2022 Korean Lipid Guidelines - Evolocumab for Whom and When? ÀÌÀåÈÆ(°æºÏÀÇ´ë)
±³À°½Ã°£ 11-26 1F, 101-102È£ 12:45~13:05 What Is the Role of Empagloflozin Heart Failure Prevention and Treatment? ±èÁ¤¼ö(ºÎ»êÀÇ´ë)
Åä·Ð 11-26 1F, 101-102È£ 13:05~13:20 Discussion ()
ÈÞ½Ä 11-26 13:20~13:40 Break ()
±³À°½Ã°£ 11-26 1F, 101-102È£ 13:40~13:50 The Fate of Angigraphically Significant Stenosis ¾ÈÁ¾È(°æ»óÀÇ´ë)
±³À°½Ã°£ 11-26 1F, 101-102È£ 13:50~14:00 Peculiar Cause of STEMI(ST-elevation Myocardial Infarction) ¹Ú°æÀÏ(µ¿¾ÆÀÇ´ë)
±³À°½Ã°£ 11-26 1F, 101-102È£ 14:00~14:10 Bailout Strategy for Coronary Artery Perforation È«½ÂÇ¥(´ë±¸°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 11-26 1F, 101-102È£ 14:10~14:20 Musculoskeletal Causes for Chest Pain À̺´ÁÖ(ºÎ»êÀÇ´ë)
Åä·Ð 11-26 1F, 101-102È£ 14:20~14:40 Discussion ()
ÈÞ½Ä 11-26 14:40~14:45 Break ()
±³À°½Ã°£ 11-26 1F, 101-102È£ 14:45~14:55 Catheter Based Management for Acute Pulmonary Thromboembolism ±èÈ«³â(°æºÏÀÇ´ë)
±³À°½Ã°£ 11-26 1F, 101-102È£ 14:55~15:05 Current Status of BPA(Bisphenol A) ±èµ¿±â(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 11-26 1F, 101-102È£ 15:05~15:15 Update: Management for Complicated Type B Aortic Dissection ·ùÇö¹Î(Â÷ÀÇ´ë)
±³À°½Ã°£ 11-26 1F, 101-102È£ 15:15~15:25 Aorta Complication Following TAVR(Transcatheter Aortic Valve Replacement) õ¹Î±¸(ºÎ»êÀÇ´ë)
Åä·Ð 11-26 1F, 101-102È£ 15:25~15:45 Discussion ()
ÈÞ½Ä 11-26 15:45~15:50 Break ()
±³À°½Ã°£ 11-26 1F, 101-102È£ 15:50~16:00 Hemodynamic Assessment in Patients with Prosthetic Aortic Valve ¼Á¤¼÷(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 11-26 1F, 101-102È£ 16:00~16:10 TAVR(Transcatheter Aortic Valve Replacement) in Patient with LV(Left ventricular) Dysfunction ±è¿õ(¿µ³²ÀÇ´ë)
±³À°½Ã°£ 11-26 1F, 101-102È£ 16:10~16:20 Experience of Transcatheter Edge-to-Edge Repair ÀÌöÇö(°è¸íÀÇ´ë)
±³À°½Ã°£ 11-26 1F, 101-102È£ 16:20~16:30 Statistics on Transcatheter Procedure for Structural Heart Disease in Yeongnam Area ¾çÅÂÇö(ÀÎÁ¦ÀÇ´ë)
Åä·Ð 11-26 1F, 101-102È£ 16:30~16:50 Discussion ()